US equities
|
MU
$938.44
▼-5.12%
META
$763.00
▲+2.70%
NVDA
$227.24
▲+0.41%
SNDK
$1,447.65
▼-2.67%
MSFT
$546.04
▲+0.90%
AAPL
$343.26
▲+0.67%
SPCX
$156.92
▼-3.98%
AMD
$596.82
▲+0.43%
MU
$938.44
▼-5.12%
META
$763.00
▲+2.70%
NVDA
$227.24
▲+0.41%
SNDK
$1,447.65
▼-2.67%
MSFT
$546.04
▲+0.90%
AAPL
$343.26
▲+0.67%
SPCX
$156.92
▼-3.98%
AMD
$596.82
▲+0.43%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Cognition Therapeutics, Inc. - Common Stock
(NQ:
CGTX
)
0.8027
-0.0542 (-6.33%)
Delayed Quote
Updated: 2:41 PM EDT, Oct 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cognition Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
Today 6:00 EDT
- An additional five years of patent protection may be possible through a standard extension -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
September 29, 2026
October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
August 06, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
June 24, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
June 16, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
May 21, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
May 14, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
May 07, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
April 07, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics CEO Issues Letter to Shareholders
March 31, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
March 26, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
March 23, 2026
Conference Call and Live Webcast Scheduled for March 26, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
March 17, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
March 02, 2026
We believe regulatory strategy expedites development of potential first treatment to address DLB psychosis
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
February 05, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
January 27, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
January 06, 2026
- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
December 03, 2025
- Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
December 01, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
November 13, 2025
Study conducted in collaboration with the Alzheimer’s Clinical Trials Consortium
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
November 06, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
September 02, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
August 27, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease
August 12, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs
August 07, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
July 29, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Power Metallic Mines (TSXV: PNPN | OTCQB: PNPNF) Issues Summer 2025 “BIG Picture” Exploration Update – More Stocks Inside
July 10, 2025
Via
AB Newswire
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
July 01, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
June 25, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
June 03, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
